Investigating Paclitaxel Toxicity in Breast Cancer: the Roles of Physical Activity and Body Composition.

This study looks into how a common breast cancer treatment, paclitaxel, can sometimes cause severe side effects that make it hard for patients to continue treatment. These side effects can significantly affect a patient's quality of life and even impact their recovery and overall health costs. What's interesting about this research is that it considers how a patient's lifestyle, specifically their physical activity levels and body makeup (like how much muscle and fat they have), might influence these side effects. The researchers are doing a detailed study with 40 women receiving paclitaxel treatment, tracking how the drug is processed in their bodies and how their body composition and physical activity might play a role in the side effects they experience. They are using a special method to monitor drug levels in the blood and are also keeping tabs on the patients' health and physical activity through questionnaires and modern tracking devices. The goal here is twofold: first, to better understand why these side effects happen to some people and not others, and second, to develop a model that can predict who might be at higher risk for these side effects based on their body composition, lifestyle, and how their body handles the drug. This could lead to more personalized treatment plans that could help reduce the risk of severe side effects and improve the overall treatment experience for patients with breast cancer. In simpler terms, this research is trying to find a way to make breast cancer treatment with paclitaxel safer and more comfortable by considering how a person's lifestyle and body type might affect their reaction to the drug. This could make a big difference in helping patients complete their treatment successfully and with a better quality of life.

NCT Number	NCT06387901
Lead Sponsor	Universitair Ziekenhuis Brussel Collaborators: Vrije Universiteit Brussel, University Ghent
Conditions	Breast Cancer, Paclitaxel Adverse Reaction, Chemotherapeutic Toxicity, Chemotherapeutic Agent Toxicity, Body Weight, Physical Inactivity
Enrollment	40 participants
Start Date	2024-07-30
Primary Completion	2025-05-06 (estimated)
Study Completion	2025-10-31 (estimated)
Updated on ClinicalTrials.gov	2024-11-01